The irinotecan-cetuximab combination and had more than 1 metastatic sites. Main clinical

aicd
이동: 둘러보기, 검색

In 37 cases the corresponding metastatic sites (all PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/25679764 liver metastases) were available for AKT and MAPK analysis (Table 2).AKT and MAPK results in primary colorectal tumoursAKT expression in primary tumours correlated with a statistically significant worse median PFS (2.4 Targeting of diverse promoter elements: the EIN3like transcrip tion elements months vs. MAPK was positive in 32 primary colorectal tumours (44 ) and negative in 40 cases (56 ). Clinical characteristics resulted well balanced across groups (Table 1).AKT and MAPK results in corresponding metastasesAnalysis on the corresponding metastatic site was performed in tumour tissue from surgical resection ofFigure 1 Kaplan-Meier curves for median progression free survival (PFS) of colorectal cancer patients treated with irinotecan and cetuximab showing phosphorylated AKT expression (----------) and without phosphorylated AKT expression (------) in either primary tumours (A, 2.4 months vs. 6.5 months, p = 0.0006) or metastases (B, 2.3 months vs. 9.2 months, p = PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/27766426 remaining 14 (38 ) (Table 2). AKT status in primary colorectal tumours was not concordant with AKT expression in metastases in 10 cases (27 ). MAPK was positive in 20 metastases (54 ) and negative in 17 cases (46 ). MAPK status in primary colorectal tumours was not concordant with MAPK expression in metastases in 11 cases (29 ). AKT expression correlated with RR (9 vs., 58 , p = 0.004), median PFS (2.3 months vs.9.2 months p PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/25679764 liver metastases) were available for AKT and MAPK analysis (Table 2).AKT and MAPK results in primary colorectal tumoursAKT expression in primary tumours correlated with a statistically significant worse median PFS (2.4 months vs.